Invivo Pharmacology Scientist
We are currently seeking a scientist to join our growing Pharmacology / Preclinical Development group.
The qualified candidate will bring their expertise in developing and characterizing xenograft, syngeneic, and PDX mode of cancer and track record with In Vivo pharmacology. An MS/Ph.D. or relevant degree is required.
Boston Biomedical is an industry leader in the creation and development of next generation cancer theraputics. Our most advanced program involves inhibitors of cancer stem cell pathways. Cancer stem cells have been shown to contribute to both recurrence and metatasis. Because cancer stem cells are thought to be resistant to current chemotherapies, we believe that focusing on stemness pathways may hold promise for advancing cancer treatment. In addition to our advanced cancer stem cell pathway inhibitor program, we have several compounds, which include peptide vaccines and immune response modifiers, in preclinical and early clinical development.
Boston Biomedical is a fully integrated oncology drug research and development company with expertise in drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing and control), global clinical trials and regulatory affairs. Our scientists have established a track record of accomplishments in a short time, including the discovery and ongoing development of multiple compounds and programs.
As our compounds moved forward in development, we began building out our commercial operations group in 2013.
Boston Biomedical has created a unique corporate work environment. We aim to continue to leverage our innovation-driven culture, scientific leadership and drug development expertise to advance the development of novel cancer therapeutics for patients with cancer.
Sat, 13 May 2017 14:42:07 PDT